Cargando…

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study

OBJECTIVE: Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied. This single-center retrospective longitudinal study was undertaken to assess the frequency o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delbarba, Andrea, Cosentini, Deborah, Facondo, Paolo, Laganà, Marta, Pezzaioli, Letizia Chiara, Cremaschi, Valentina, Alberti, Andrea, Grisanti, Salvatore, Cappelli, Carlo, Ferlin, Alberto, Berruti, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108714/ https://www.ncbi.nlm.nih.gov/pubmed/37077359 http://dx.doi.org/10.3389/fendo.2023.1128061

Ejemplares similares

Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status
por: Turla, Antonella, et al.
Publicado: (2023)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
por: Rossini, Elisa, et al.
Publicado: (2021)

Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Case Report: Hypothalamic Amenorrhea Following COVID-19 Infection and Review of Literatures
por: Facondo, Paolo, et al.
Publicado: (2022)

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
por: Fiorentini, Chiara, et al.
Publicado: (2019)

Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
por: Rossini, Elisa, et al.
Publicado: (2021)

Endocrine system after 2 years of COVID-19 vaccines: A narrative review of the literature
por: Pezzaioli, Letizia Chiara, et al.
Publicado: (2022)

Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy
por: Cosentini, Deborah, et al.
Publicado: (2021)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series
por: Tőke, Judit, et al.
Publicado: (2022)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis
por: Turla, Antonella, et al.
Publicado: (2022)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
por: Tamburello, Mariangela, et al.
Publicado: (2023)

Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells
por: Abate, Andrea, et al.
Publicado: (2020)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
por: Ambrosini, Roberta, et al.
Publicado: (2020)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma
por: Weng, Yan, et al.
Publicado: (2023)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

THU617 Prolonged Exposure To Target Mitotane Concentrations Is Associated With Better Recurrence-free Survival In Patients With Adrenocortical Carcinoma On Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2023)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience
por: Pezzaioli, Letizia Chiara, et al.
Publicado: (2020)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hnoaq9uoo5ks62f2bg98dmvtf3